Gosset Ownership
Private
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Rugen Therapeutics General Information
Rugen Therapeutics is a pre-clinical biotechnology company developing novel, first‑in‑class small‑molecule drugs for multiple central nervous system and psychiatric indications; as of publicly available information its programs remain in preclinical development with efficacy shown only in animal models of autism spectrum disorder and obsessive compulsive disorder.[4][3][5]
Drug Pipeline
No pipeline data available
Key Partnerships
Allergan (exclusive collaboration for small‑molecule therapies for autism spectrum disorders and obsessive compulsive disorders)[4], McQuade Center for Strategic Research and Development (collaboration to develop novel treatments for diverse psychiatric disorders)[1][5]
Rugen Therapeutics Funding
No funding data available
To view Rugen Therapeutics's complete valuation and funding history, request access »